Compare Becton Dickinson and Co (BDX) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares China Large-Cap ETF — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while iShares China Large-Cap ETF trades at $35.3. The key difference: Becton Dickinson and Co pays a 2.34% dividend while iShares China Large-Cap ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| BDX | FXI | |
|---|---|---|
Market Cap | $48.93B | — |
Sector | Health | — |
52-Week High | $185.39 | $41.75 |
52-Week Low | $138.62 | $31.59 |
Enterprise Value | $65.03B | — |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
FXI, the iShares China Large-Cap ETF, trades at $36.17, up 0.61% on the day, with a bullish technical signal driven by moving averages. The ETF benefits from China's strong export data and state-backed economic support, though key financial ratios are not disclosed in the provided data. Recent news highlights China's AI and manufacturing strength as positive catalysts.
Outlook is cautiously optimistic given bullish technicals and macroeconomic tailwinds, but risks include U.S.-China tensions and reliance on financials-heavy exposure. The dividend announcement for 2026 provides income appeal, yet investors face volatility from geopolitical and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
